New research indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end traditional lifestyle regimens.
Findings released in a prominent medical journal points out that while overweight people frequently drop about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these drugs need to be cognizant of the potential of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
This pace of regain means a reversion to original weight within about a year and a half.
Comparing Therapies
The research, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers note that people who lose weight through dieting usually see a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Quick Regain
Doctors believe the way of the injections accounts for the heightened regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means appetite is uncontrolled, making binge eating much more probable."
An Ongoing Disease?
Health authorities suggest the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of relapse, the treatment is often long-term.
This opinion is echoed by pharmaceutical companies, who say that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like hypertension.
User Experiences
People who have come off the medication explain a powerful return of cravings.
"I experienced something that goes on and I was suddenly starving," said a patient.
The struggle is worsened if individuals have not established lasting lifestyle or habit changes during therapy.
Growing Use
Figures suggest that millions of people in the UK have used these injections in the past year, with interest remaining high.
- Use is greater among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a standalone cure and long-term success relies on integrated lifestyle changes.
